AU768219B2 - Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof - Google Patents

Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof Download PDF

Info

Publication number
AU768219B2
AU768219B2 AU31065/00A AU3106500A AU768219B2 AU 768219 B2 AU768219 B2 AU 768219B2 AU 31065/00 A AU31065/00 A AU 31065/00A AU 3106500 A AU3106500 A AU 3106500A AU 768219 B2 AU768219 B2 AU 768219B2
Authority
AU
Australia
Prior art keywords
azithromycin
ethanolate
water
suspension
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31065/00A
Other languages
English (en)
Other versions
AU3106500A (en
Inventor
Judith Aronhime
Claude Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22332273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU768219(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU3106500A publication Critical patent/AU3106500A/en
Application granted granted Critical
Publication of AU768219B2 publication Critical patent/AU768219B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU31065/00A 1998-11-30 1999-11-30 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof Ceased AU768219B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11029898P 1998-11-30 1998-11-30
US60/110298 1998-11-30
PCT/US1999/028368 WO2000032203A1 (en) 1998-11-30 1999-11-30 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
AU3106500A AU3106500A (en) 2000-06-19
AU768219B2 true AU768219B2 (en) 2003-12-04

Family

ID=22332273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31065/00A Ceased AU768219B2 (en) 1998-11-30 1999-11-30 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof

Country Status (26)

Country Link
US (1) US6365574B2 (enExample)
EP (2) EP1152765B1 (enExample)
JP (1) JP2002531409A (enExample)
KR (1) KR100603226B1 (enExample)
CN (2) CN1273142C (enExample)
AP (1) AP1709A (enExample)
AT (1) ATE279200T1 (enExample)
AU (1) AU768219B2 (enExample)
BG (1) BG105547A (enExample)
CA (1) CA2352562A1 (enExample)
CZ (1) CZ20011886A3 (enExample)
DE (1) DE69921192T2 (enExample)
DK (1) DK1152765T3 (enExample)
ES (1) ES2229804T3 (enExample)
HK (1) HK1043725B (enExample)
HU (1) HUP0104241A3 (enExample)
IL (1) IL143376A0 (enExample)
LV (1) LV12735B (enExample)
NZ (1) NZ512496A (enExample)
PL (1) PL197894B1 (enExample)
PT (1) PT1152765E (enExample)
RO (1) RO121408B1 (enExample)
RU (1) RU2240124C2 (enExample)
SI (1) SI20639A (enExample)
WO (1) WO2000032203A1 (enExample)
ZA (1) ZA200104312B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
EP1152765B1 (en) * 1998-11-30 2004-10-13 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
UA76967C2 (uk) * 2000-11-27 2006-10-16 Сандоз Аг Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання
PL207076B1 (pl) * 2000-11-27 2010-10-29 Sandoz Ag Sposób wytwarzania jednowodzianu azytromycyny
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
EP1390377B1 (en) 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin
EP1671979B1 (en) * 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
DK1446010T3 (da) 2001-10-18 2009-06-22 Teva Pharma Stabiliseret azithromycin-sammensætning
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
NZ534234A (en) * 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
CA2591744A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
US20090318375A1 (en) * 2005-06-08 2009-12-24 Hanmi Pharm Co., Ltd Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same
US9433516B2 (en) * 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
MX2011009548A (es) 2009-03-13 2011-12-14 Da Volterra Composiciones y metodos para la eliminacion de bacterias gram-negativas.
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN103983730B (zh) * 2014-06-11 2015-09-30 北京市药品检验所 阿奇霉素或其制剂中的杂质检查方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1161971A (zh) * 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
EP1152765B1 (en) * 1998-11-30 2004-10-13 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
KR100491183B1 (ko) * 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
EP1390377B1 (en) * 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin

Also Published As

Publication number Publication date
HK1043725B (en) 2005-05-06
AU3106500A (en) 2000-06-19
ZA200104312B (en) 2001-11-28
CN1737008A (zh) 2006-02-22
DE69921192D1 (de) 2004-11-18
CN1273142C (zh) 2006-09-06
BG105547A (en) 2001-12-31
US6365574B2 (en) 2002-04-02
CN100339384C (zh) 2007-09-26
PL197894B1 (pl) 2008-05-30
CZ20011886A3 (cs) 2001-10-17
EP1152765A1 (en) 2001-11-14
AP2001002183A0 (en) 2001-06-30
HK1043725A1 (en) 2002-09-27
SI20639A (sl) 2002-02-28
HUP0104241A3 (en) 2003-12-29
ES2229804T3 (es) 2005-04-16
PT1152765E (pt) 2004-12-31
KR100603226B1 (ko) 2006-08-28
LV12735B (en) 2002-03-20
HUP0104241A2 (hu) 2002-03-28
EP1484062A1 (en) 2004-12-08
EP1152765A4 (en) 2002-07-17
RO121408B1 (ro) 2007-05-30
RU2240124C2 (ru) 2004-11-20
US20020007049A1 (en) 2002-01-17
CA2352562A1 (en) 2000-06-08
ATE279200T1 (de) 2004-10-15
AP1709A (en) 2007-02-27
EP1152765B1 (en) 2004-10-13
KR20010099806A (ko) 2001-11-09
PL347971A1 (en) 2002-05-06
DE69921192T2 (de) 2006-02-16
DK1152765T3 (da) 2005-01-31
CN1334735A (zh) 2002-02-06
IL143376A0 (en) 2002-04-21
JP2002531409A (ja) 2002-09-24
LV12735A (en) 2001-10-20
NZ512496A (en) 2003-02-28
WO2000032203A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
AU768219B2 (en) Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
WO2000032203A9 (en) Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
EP1254146B1 (en) Processes for preparing clarithromycin polymorphs and novel polymorph iv
EP2125850B1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
EP1280535B1 (en) Processes for preparing clarithromycin polymorphs
EP1246831B1 (en) Preparation method of azithromycin dihydrate
EP0827965B1 (en) Synthesis of 9-deoxo- 9a-aza 11,12-deoxy- 9a-methyl-9a-homoerythromycin A 11,12- hydrogenorthoborate dihydrate
JP2000229993A (ja) 新規のエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
IE74885B1 (en) Pharmaceutical compounds
EP2513130B1 (en) Composition comprising an amorphous non-crystalline glass form of roxithromycin
JP2003503506A (ja) ４”−置換−９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシン誘導体の二リン酸塩及びその医薬組成物
JPH0687881A (ja) ロキタマイシン・一水和物結晶、及びその製造法
RS51299B (sr) Kristalne forme makrolidnih jedinjenja koje ispoljavaju anti-inflamatornu aktivnost
JP2003534231A (ja) 新規の６−デオキシエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
JPWO1999021868A1 (ja) エリスロマイシンａ誘導体
JPS58213796A (ja) 新規３″−アシル化マクロライド系抗生物質
HK1134096A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)